The rise of the healthcare social media influencer
June 7, 2021 | digital health, digital strategy, digital tools, disease awareness, multichannel strategy, omnichannel strategy, social media
The consumer industry has long been leveraging the power of social media influencers with enormous success. But can the highly regulated healthcare industry achieve the same results? Daniel Brackins explores the influencer marketing opportunities for life science companies and answers your questions.
Over the past few months, consumer trust has waned across all institutions, from the government to the media. Trust in traditional sources is now at an all‑time low. However, despite this decline, consumers still trust business. Moreover, according to the Edelman Trust Barometer, the only institutions considered both competent and ethical are businesses.1
At the same time, we’re seeing a revolution in the role of the voice of the consumer, with 68% of people believing consumers have the power to force businesses to change.1 Today, the most trusted spokespeople in society are academic experts and the every‑day person — more than the government, CEOs, and journalists.
Healthcare and pharmaceutical companies now have an opportunity to not only make their own voices heard but to partner with patient influencers, who have built large followings based on their authenticity and relatability.
Consumer businesses often view social media influencers as a way to speak to their audiences using a trusted persona. While healthcare has been slow to adopt the influencer voice, influencers can help healthcare companies to build trust, especially in an era dominated by fake news with these individuals can also enable life science companies to elevate the patient voice in their communications, leading to a more patient‑centric brand.
Social media platforms have democratized the creation and dissemination of information—anyone can express an opinion and share it with their followers. Their content extends to in‑depth customer reviews and highly personal stories that drive disease awareness.
Consider that when an influencer shares content, 93% of followers are likely to ask their physicians or healthcare professionals for more information about a specific medication, when an influencer shares information about a specific medication, 87% of followers are likely to ask their physician or healthcare professional about the treatment.2
In contrast, studies show that celebrities have very little influence on decision‑making within healthcare. Researchers found that including a celebrity voice in a campaign did not inspire the patient to act and search for more information, discuss the disease with their doctor, or ask for a prescription—the same holds true for expert endorses.3,4
While expert endorsers, or key opinion leaders, remain important for building trust, they are less effective in the diffusion of prescription drug information among consumers.5 Experts make a product or brand credible, but patients see consumer influencers as their trusted peers. Their content is more relatable, especially for patients who are less health literate. As a result, the most powerful campaigns combine the voices of experts and consumer influencers.
READ THE FULL ARTICLE HERE
This content was provided by Avalere Health
Company Details
Latest Content from Avalere Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...
Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients
The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.
Shaping the dermatology landscape: Independent expert analysis of the pipeline in 5 disease areas
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.
How the WHO hepatitis strategy measures up in the field
With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...